Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02117635
Other study ID # RN01-CP-0002
Secondary ID 2012-003482-18
Status Completed
Phase Phase 2
First received
Last updated
Start date June 2014
Est. completion date August 16, 2017

Study information

Verified date April 2018
Source ReNeuron Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim of this Phase II trial is to determine whether it is sufficiently likely that CTX DP treatment at a dose level of 20 million cells improves the recovery in the use of the paretic arm in acute stroke patients to justify a subsequent larger prospectively controlled study.

This study will evaluate the safety and efficacy of intracerebral CTX DP at a dose level of 20 million cells in patients with paresis of an arm following an ischaemic middle cerebral artery (MCA) stoke. Eligible patients will have no useful function of the paretic arm a minimum of 28 days after the ischaemic stroke (a modified NIH Stroke Scale (NIHSS) Motor Arm Score of 2, 3 or 4 for the affected arm).


Description:

Design: This Phase II efficacy trial is a multi-centre, open label, single arm, non-comparative design, administering a single dose of CTX cells 2 to 3 months post-ischaemic stroke with follow-up over 12 months. The trial will be overseen by an independent DSMB. The DSMB will adjudicate at predetermined intervals whether a patient has satisfied the primary response criterion and whether the ongoing safety profile justifies continuation or modification of the study.

At least 21 patients will be enrolled to receive CTX DP (20 million cells) by stereotaxic intra-striatal injection ipsilateral to the location of the MCA ischaemic stroke.

Pre-treatment selection of patients: Men and women, aged 40 or more, supratentorial ischaemic stroke or a stroke with elements of both in an area perfused by the MCA (i.e. stroke due to ischaemia resulting in infarct located in the basal ganglia, internal capsule, or corona radiata or a stroke due to ischaemia resulting in infarction of part of the cerebral cortex).

Patients with a first stroke within the past 4 weeks (at time of consent) satisfying the following criteria: Modified NIHSS Motor Arm Score of 2 (some effort against gravity), 3 (no movement against gravity) or 4 (no movement) for the paretic arm post ischaemic stroke; Clinical diagnosis of stroke confirmed by physician using neuro-imaging (computerised tomography or magnetic resonance imaging). A Score of 0 or 1 for test 2 of the ARAT at visit 1 and 2 using the affected arm.

Treatment: One patient will be treated at one time. A single dose (20 million) of CTX DP cells will be administered intracranially via stereotaxic neurosurgery.

Post-treatment follow-up: Patients will be followed for 12 months post-implantation.

End-points: The primary endpoint of the trial is efficacy, using ARAT. Secondary endpoints are efficacy and safety. Outcome measures for efficacy include Fugl-Meyer, NIHSS, BI and RFA. Safety will be assessed by incidence of relevant adverse events monitoring patient's general physical condition and clinical measures (temperature, pulse rate and rhythm, ECG, blood pressure, full blood count, liver function tests, serum urea and electrolytes), immunological response and concomitant medications at the 7 follow-up visits to the clinic in the first year after treatment.

Post-trial follow-up: Annual correspondence with family practitioners; Life-long follow-up for new diagnosis of cancer, site of primary tumour, and survival via National Cancer Registry.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date August 16, 2017
Est. primary completion date October 31, 2016
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria:

- Written informed consent or witnessed informed consent in the event that the patient is unable to sign informed consent due to paresis of the affected arm.

- Supratenorial ishaemic stroke

- Male or female aged 40 years or more.

- Stroke, at time of consent, satisfying the following criteria:

- Modified NIHSS Motor Arm Score of 2, 3 or 4 for affected arm visit 1 and visit 2.

- Clinical diagnosis of stroke confirmed by physician using neuro-imaging (CT or MRI).

- A Score of 0 or 1 for test 2 of the ARAT on day 28+7 and day 56+7 post-stroke using the affected arm.

- Ability to comprehend verbal commands.

- Eligible for neurosurgery including appropriate anatomical target for cell implantation.

Exclusion criteria:

- - Prior history of stroke resulting in permanent moderate to severe disability (i.e. Rankin Scale greater than 2) (other than the presenting ischaemic stroke).

- Stroke due to haemorrhage.

- History of neurological or other disease resulting in significant functional impairment of the paretic arm impairing potential ability to pick up, lift and place a 2.5 cm3 block (e.g. Parkinson's disease, motor neuron disease, arthritis, Dupuytren's contracture or fixed anatomical abnormality).

- Any contraindications to MRI including presence of a cardiac pacemaker (excluding MR-conditional cardiac pacemaker), metal fragments in eye etc.

- Uncontrolled blood pressure defined as systolic blood pressure =180 mm Hg or diastolic blood pressure =110 mm Hg (patients are only to be excluded if an initial value exceeding these limits is repeated on retesting over several days).

- Patient with a severe comorbid disorder, not expected to survive more than 12 months.

- Acute cardiovascular events other than the presenting ischaemic stroke (e.g. myocardial infarction, recent coronary intervention for symptomatic cardiac disease) considered by the Investigator or the anaesthetist responsible for the patient to place the patient at increased anaesthetic risk, 3 months prior to planned injection of CTX0E03 DP.

- History of malignant disease (except for non-melanoma skin cancer) within the previous 5 years or any history of malignant brain tumours or brain metastasis.

- Current treatment with tamoxifen.

- Patients taking valproate drugs for any indication in whom it is not considered appropriate to discontinue the valproate for a period of one week prior and four weeks post neurosurgery. Patients in whom valproate is switched to an alternative agent during this period may be included.

- Requirement for antiplatelets and/or anticoagulants including heparin, warfarin or other anticoagulants/ medication that can not be interrupted to allow surgery.

- Requirement for intermittent (stop/start date from 1-month prior-to and 3 month post- CTX0E03 DP administration) use of oral antispasticity medications (oral antispasticity medications are acceptable if they have been taken regularly for at least one month prior to CTX0E03 DP administration).

- A history of uncontrolled diabetes e.g. history of hypoglycaemic or hyperglycaemic events requiring hospital admission over previous 6 months.

- Females of childbearing potential (FOCBP) (or within 2 years of last menstrual cycle) must have a confirmed negative pregnancy test at time of treatment and agree to use two reliable methods of contraception (e.g. oral contraceptive and condom, intra-uterine device (IUD) and condom, diaphragm with spermicide and condom) for the duration of this study

- Sexually active males with partners who are FOCBP must be willing to use a reliable method of contraception (e.g. barrier and spermicide or as described above) for the duration of this study.

- Considered unlikely to be able to attend for all follow-up visits.

- Organ transplant recipient

- In the opinion of the investigator, sustained consumption of alcohol or drugs at a level likely to be injurious to health.

Study Design


Intervention

Biological:
CTX DP
20 million cell dose administered by surgery to the damaged area of the brain

Locations

Country Name City State
United Kingdom Queen Elizabeth Hospital Birmingham
United Kingdom NHS Southern General Hospital Glasgow
United Kingdom Kings College Hospital London
United Kingdom University College London Hospital London
United Kingdom Royal Victoria Infirmary Newcastle
United Kingdom Nottingham City Hospital Nottingham
United Kingdom SalfordRoyal NHS Foundation Trust Salford
United Kingdom Royal Hallamshire Hosptial Sheffield
United Kingdom Southampton Hospital Southampton

Sponsors (1)

Lead Sponsor Collaborator
ReNeuron Limited

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Yozbatiran N, Der-Yeghiaian L, Cramer SC. A standardized approach to performing the action research arm test. Neurorehabil Neural Repair. 2008 Jan-Feb;22(1):78-90. Epub 2007 Aug 17. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Action Research Arm Test (ARAT) The primary outcome measure is a minimum 2 point improvement in the ARAT test number 2 (Yozbatiran et al., 2008).
Response will be defined as a minimum improvement of 2 points in test number 2 of the ARAT (Grasp a 2.5 cm3 block and move it from the starting position to the target end position) in the affected arm 6 months after injection of CTX DP. This would represent an improvement from a pre-treatment state in which the patient was unable to grasp and reposition the block as required to a post-treatment state in which the patient could accomplish the task as specified within 60 seconds.
3 months
Secondary To assess the efficacy of intracranial CTX DP in restoring upper limb function following an ischaemic stroke using the ARAT 12 months
Secondary To assess the efficacy of intracranial CTX DP in restoring function following an ischaemic stroke using the Modified National Institutes of Health Stroke Scale (NIHSS) 12 months
Secondary To assess the efficacy of intracranial CTX DP in restoring patient's functional independence following an ischaemic stroke using the Rankin Focused Assessment (RFA) version of the modified Rankin Scale 12 months
Secondary To assess the efficacy of CTX DP in improving patient's ability to execute activities of daily living following an ischaemic stroke using the Barthel Index (BI) 12 months
Secondary To assess the safety and tolerability of intracranial CTX DP in patients following an ischaemic stroke Incidence of adverse events: monitoring of vital signs, temperature, pulse rate and rhythm, ECG, blood pressure, full blood count, liver function test, serum urea and electrolytes, CTX antibody screen 12 months
Secondary To assess the efficacy of intracranial CTX DP in restoring upper limb function following an ischaemic stroke using the Fugl-Meyer 12 months
See also
  Status Clinical Trial Phase
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Completed NCT03780296 - Implementing Technology Enhanced Real Time Action Observation Therapy in Persons With Chronic Stroke N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Recruiting NCT05163210 - Effectiveness of AOT Based on Virtual Reality in Stroke Rehabilitation. N/A
Terminated NCT04113525 - Transcutaneous Spinal and Peripheral Stimulation and Wrist Robotic Therapy for Patients With Spastic Stroke N/A
Completed NCT01948739 - Brain Machine Interface Control of an Robotic Exoskeleton in Training Upper Extremity Functions in Stroke N/A
Not yet recruiting NCT03237520 - Comparing Virtual Reality Therapy With Modified-CIMT Versus Modified-CIMT Alone in Hemiparetic Children N/A
Completed NCT03080454 - The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke Phase 1/Phase 2
Completed NCT01651533 - Mental Practice in Chronic, Stroke Induced Hemiparesis N/A
Suspended NCT01519843 - Post Stroke Motor Learning N/A
Completed NCT01106755 - Effects of Ground Level Gait Training With Body Weight Support (BWS) and Functional Electrical Stimulation (FES) N/A
Active, not recruiting NCT00170716 - Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity Hemiparesis Phase 3
Completed NCT04286997 - VARA (Virtual and Augmented Reality Applications in Rehabilitation): Motor Rehabilitation Protocol With GRAIL for Patients Affected by Hemiparesis N/A
Completed NCT05856669 - The Effects of Mirror-Based Virtual Reality Systems and Recalibration Software on Upper Extremity Function in Individuals Experiencing Hemiparesis Post-Stroke N/A
Recruiting NCT05801874 - Gait and Posture Analysis in Hemiparetic Patients Through Optoelectronic Systems, "Smart" Tools and Clinical Evaluation
Recruiting NCT05590988 - Sensorimotor Arm Rehabilitation After Stroke N/A
Completed NCT04536987 - Robot Therapy for Rehabilitation of Hand Movement After Stroke Phase 2
Recruiting NCT04694833 - Telerehabilitation Through Serious Games in Virtual Reality in a Stroke Population (AutoRReVi) N/A
Completed NCT03965403 - Upper Extremity Rehabilitation With the BURT Robotic Arm N/A
Not yet recruiting NCT03638570 - Altered Connections in the Spinal Cord to Reduce Hand Impairment After Stroke N/A